XTalks

NOVEMBER 7, 2022

These tumor-derived entities are used to derive genomic and proteomic data. Gleich, MD, FACS, Senior Vice President, Medical Department, and Dr. Christopher Huth, PhD, Senior Clinical Trial Manager, Clinical Trial Management. Liquid Biopsy Use in Oncology Clinical Trials.

Clinical Trials 98

Clinical Trials Clinical Trials Trials FDA Approval 98

Drug Discovery World

APRIL 24, 2023

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio. Register now. The post Free webinar today: How is NGS informing oncology drug discovery?

RNA 52

RNA Drugs Genome Genomics 52

Drug Discovery World

APRIL 18, 2023

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio. Register now.

RNA 52

RNA Drugs Genome Genomics 52

Drug Discovery World

APRIL 11, 2023

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio. Register now.

RNA 52

RNA Drugs Genome Genomics 52

Drug Discovery World

APRIL 4, 2023

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio. Register now.

Drugs 52

Drugs RNA Genome Genomics 52

Drug Discovery World

APRIL 3, 2023

You will hear from Darrell Green, a lecturer in RNA Biology at Norwich Medical School, Panna Sharma, CEO of Lantern Pharma, as well as Dr Stephane Budel and Dr Miguel Edwards, Founding Partner and Partner at DeciBio.

RNA 52

RNA Drugs Genome Genomics 52

Worldwide Clinical Trials

JUNE 15, 2022

Further, some patients are still hesitant to go into the clinic, and the prevalence of misinformation from the pandemic has led to greater concerns about therapies like gene therapies and the impact they fear it will have on their RNA/DNA. Working with a centralized IBC/IRB provider can speed up your process. .

Gene Therapy 130

Gene Therapy Gene Clinical Trials Clinical Trials 130

The Pharma Data

AUGUST 16, 2021

The antiviral agent incorporates RNA-like building blocks into the RNA genome of the virus. If this genetic material is further replicated, defective RNA copies are produced and the pathogen can no longer spread. Molnupiravir is currently being tested in clinical trials.

RNA 52

RNA Drugs Genome Genomics 52

Drug Discovery World

FEBRUARY 13, 2023

SB: Transcriptomics is the study of genomic RNA transcripts in a biological system. RNA transcript expression levels can provide insight into underlying biology – eg. In terms of technical process, traditional RNA sequencing was a very laborious process that could take several weeks and was prone to errors. SB: Certainly.

RNA 52

RNA Drugs Gene Expression Gene 52

Drug Discovery World

OCTOBER 19, 2022

Yapan Bio has expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, India, which has enhanced its ability to support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids. .

Development 52

Development Gene Therapy RNA DNA 52

Pharmaceutical Technology

JULY 5, 2022

It was also found in lab experiments that ZCCHC14, a protein that interacts with zinc, attaches to certain part of HAV’s ribonucleic acid (RNA), enabling the virus to recruit TENT4 from the human cell. HAV usually hijacks TENT4 and utilises it for the replication of its own genome.

Protein 130

Protein RNA Genome Genomics 130

Delveinsight

SEPTEMBER 14, 2021

ADARx bags USD 75 Million to advance its RNA tech pipeline. ADARx Pharmaceuticals, a biotechnology company developing RNA targeting therapeutics , announced the completion of a USD 75 million Series B financing to progress its drug development pipeline. SR One Capital Management and OrbiMed Advisors co-led Series B. Simeon George, M.D.,

RNA 67

RNA Clinical Trials Clinical Trials Drugs 67

pharmaphorum

SEPTEMBER 14, 2021

The Cambridge, Massachusetts biotech is focusing specifically on the 60% of DNA sequences that repeat themselves hundreds or thousands of times in the genome, known as the ‘repeatome’, that could contain targets for cancer and autoimmune disorders. That muffles the immune system response and allows the cancer to grow.

DNA 52

DNA Immune Response Genome Genomics 52

XTalks

NOVEMBER 30, 2023

Over 26 weeks of Sunlenca combined with other antiretroviral drugs, 81 percent of participants achieved HIV RNA suppression, reaching levels low enough to be considered undetectable. Both trials concluded with maintained virologic suppression, and no clinically significant change from baseline in CD4+ cell counts was observed.

FDA Approval 111

FDA Approval Gene Therapy Clinical Trials Clinical Trials 111

The Pharma Data

SEPTEMBER 28, 2020

Accenture Applied Intelligence announced a new data and analytics approach to manage and derive insights from paediatric acute myeloid leukaemia (AML) genomic data, with the potential to improve precision medicine. Insights from project could potentially improve precision medicine use for paediatric AML.

Genome 52

Genome Genomics Clinical Trials Clinical Trials 52

Pharmaceutical Technology

DECEMBER 14, 2022

The alliance will merge the PRISM oligonucleotide platform of Wave and the capabilities of GSK in genetics and genomics. An RNA editing therapy, WVE-006, could act on AATD’s liver and lung manifestations. On completion of the first-in-patient clinical trial by Wave, GSK will be in charge of the development and marketing works.

Life Science 162

Life Science Development Gene Therapy Genetics 162

Drug Discovery World

MARCH 13, 2024

In 2019 he was part of a research team which discovered humanised antibody, PRL3-zumab, was effective at shrinking PRL3 over-expressing tumours, and which has since been approved for Phase II clinical trials in Singapore, the US and China. There has also been significant investment in infrastructure in the country.

Life Science 69

Life Science Genome Genomics Research 69

Drug Discovery World

JANUARY 23, 2023

Following the release of Clarivate’s report ‘RNA Technology Companies to Watch’, DDW’s Diana Spencer speaks to Strand Therapeutics’ Jacob Becraft and HAYA Therapeutics’ Samir Ounzain to find out how this technology could revolutionise disease treatment. DS: How will your work ultimately impact disease treatment?

RNA 98

RNA Genome Genomics Engineer 98

Drug Discovery World

AUGUST 16, 2023

.” The findings suggest it might be possible to predict who will benefit from carboplatin and docetaxel using a range of different biomarkers and suggest further investigation of these biomarkers in clinical trials is warranted.

Genetics 52

Genetics Gene Hormones RNA 52

The Pharma Data

OCTOBER 19, 2020

With over 300 active clinical trials, Winship researchers are dedicated to taking new cancer treatments from bench to bedside. cancer centers selected as a Lead Academic Participating Site for the NCI’s National Clinical Trials Network (NCTN). Winship is one of 32 U.S.

Life Science 52

Life Science Clinical Trials Clinical Trials RNA 52

Drug Discovery World

DECEMBER 21, 2023

Regulatory issues and diversity in clinical trials were also important in 2023, as well as the role that artificial intelligence tools like ChatGPT might play. In a record year for gene therapy approvals, it isn’t surprising that cell & gene therapy (CGT) has been a hot topic.

Gene Therapy 59

Gene Therapy Gene Antibody FDA Approval 59

Drug Discovery World

MAY 5, 2023

Anthony Schmitt , PhD, Senior Vice President, Science at Arima Genomics, discusses the applications of 3D genomics in cancer research. But what about the patients whose genomic tests do not identify a cancer driver matched to an existing targeted therapy? with regards to detecting cancer driver mutations.

Genome 52

Genome Genomics Gene Genetics 52

Drug Discovery World

JANUARY 21, 2024

He has founded and led three bio-AI technology companies, each of which led revolutions in medicine, genomics, agriculture, and conservation. Protein and RNA-based therapeutics development is a challenging multidimensional problem, accompanied by an equally challenging scalable manufacturing process.

Protein 52

Protein Vaccination Vaccine Development 52

The Pharma Data

MARCH 23, 2022

Polymerase is a viral protein that directs how Ebola virus replicates its genome as it infects new hosts. Back in 2018, researchers tested a broad-spectrum antiviral candidate called remdesivir/VEKLURY, which acts as a nucleotide decoy to get incorporated into the viral RNA genome and stop viral polymerase.

Protein 52

Protein Genome Genomics Research 52

pharmaphorum

SEPTEMBER 22, 2022

Le Vert says Osivax’s technology differs, however, as it attacks the virus’ T-cells, making the vaccine more effective in the long term, and that clinical trials have shown promise. Over 800 subjects have been recruited for four clinical trials, with 72 to 300 subjects in the various trials.

Vaccination 97

Vaccination Vaccine Antibody Clinical Trials 97

Drug Discovery World

APRIL 6, 2023

She is being recognised for her longstanding commitment as a patient advocate for American Indian Tribes across the Mountain West and beyond, and for her commitment to improving health literacy and clinical trial enrolment among American Indian populations. Jane Perlmutter, PhD, MBA, is President and Founder of the Gemini Group.

Protein 52

Protein Clinical Trials Clinical Trials Antibody 52

Drug Discovery World

AUGUST 1, 2023

1 August was first chosen as World RNA Day in 2018 as a play on AUG (adenine, uracil and guanine), a triple sequence of RNA (called a codon) that initiates protein synthesis by the cell. Another potential clinical pathway is to use engineered exogenous circRNAs to produce therapeutic proteins within target cells.

RNA 52

RNA Drugs Gene Silencing Vaccination 52

Drug Discovery World

APRIL 30, 2024

Messenger RNA (mRNA) has come into focus within the drug discovery and development as an exciting tool to deliver genetic information. mRNA is a molecule made up of a single strand of ribonucleic acid (RNA). At the start of 2024, the first patients in a clinical trial investigating an mRNA cancer therapy were dosed.

RNA 52

RNA Protein Vaccination Vaccine 52

The Pharma Data

JANUARY 17, 2021

That’s not the case with RNA-targeted drugs. Safety is critical in all clinical trials, but with ultra-rare diseases, even greater care is taken. We’ve created safety databases that begin with non-human primates and extend to controlled clinical trials.” they can help many patients.”.

Genetics 52

Genetics Clinical Trials Clinical Trials Drugs 52

Drug Discovery World

JANUARY 2, 2024

As for Infinitopes, the company’s trials will begin in 2024. It’s an exciting time, to learn which will be the best solutions for patients.” Technologies to enable cancer research Dr Errico noted the huge impact of genome sequencing, genomic tools, and RNA sequencing on cancer research.

Research 59

Research Vaccination Vaccine Medicine 59

Drug Discovery World

JULY 11, 2023

Now, with the growth of publicly available genomics, transcriptomics, and proteomics databases, the ability to quickly carry out large-scale DNA, RNA, and protein screenings, and the availability of massive sets of de-identified patient data, the amount of high-value, analysable data has reached enormous proportions.

Big Data 40

Big Data Development Life Science Drugs 40

Drug Discovery World

JANUARY 17, 2024

Brett Swansiger, Chief Commercial Officer at ANGLE discusses the importance of liquid biopsies in precision medicine trials for cancer. Furthermore, oncology clinical trials are frequently challenged by low enrolment rates, failure to achieve primary endpoints, study design complexity and limited funding 5.

Medicine 59

Medicine DNA Genome Genomics 59

Drug Discovery World

OCTOBER 4, 2022

The pandemic might have affected the number of clinical trials taking place for cell and gene therapies, with activity decreasing by around 15% compared to 2020, but major therapies such as Novartis’ gene therapy drug for spinal muscular atrophy (SMA) Zolgensma still made it to market. .

Gene Therapy 52

Gene Therapy Drugs Gene Manufacturing 52

Drug Discovery World

SEPTEMBER 6, 2022

And whilst clinical trials activity decreased by around 15% compared to 2020, last year still saw a number of regenerative medicines reach the bedside. According to the ASGCT, the gene therapy pipeline increased 16% from Q1 2021 with 3,579 gene, cell, and RNA therapies in development from preclinical through pre-registration stages.

Gene Therapy 52

Gene Therapy Gene Manufacturing Medicine 52

Drug Discovery World

JULY 26, 2023

With 100-fold the number of genes in the human genome 1 , this microbial collection is a rich genetic signature of clinical significance that we have only recently gained the tools to explore. Genome editing tools such as CRISPR may be employed to create “live biotherapeutics” (drugs composed of living bacteria).

Medicine 52

Medicine Genome Genomics Bioinformatics 52

The Pharma Data

DECEMBER 10, 2020

Both vaccination regimens resulted in complete protection from subsequent viral ‘challenge’ as reflected by reductions in viral RNA levels that were below the level of detection by day seven post-challenge compared to controls. Additional safety and neutralizing data are currently being collected/analyzed.

Vaccination 52

Vaccination Vaccine Immune Response Protein 52

Delveinsight

DECEMBER 13, 2020

Even though clinical trial results were promising, adverse events and serious complications were observed. HBV DNA can be integrated into the host genome. New antiviral drugs in clinical trials include entry receptor inhibitors, capsid assembly modifiers, RNA interference, and nucleic acid polymers.

Genotype 52

Genotype FDA Approval DNA Drugs 52